| Income Statement | 2025-09-30 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues and other income | 115,461 | 51,812 | 41,531 | |
| Cost of captisol | 3,801 | 2,449 | 2,906 | |
| Amortization of intangibles | 8,097 | 8,258 | 8,257 | |
| Research and development | 21,019 | 5,675 | 5,354 | |
| General and administrative | 28,446 | 24,475 | 17,623 | |
| Financial royalty assets impairment | 0 | - | 26,491 | |
| Fair value adjustments to partner program derivatives | 833 | -7,812 | - | |
| Total operating costs and expenses | 60,530 | 48,669 | 60,631 | |
| Operating income (loss) | 54,931 | 3,143 | -19,100 | |
| Gain (loss) from short-term investments | 7,798 | 2,407 | -14,256 | |
| Gain (loss) from change in fair value of equity-method investments and other investments | 75,887 | - | - | |
| Interest income | 3,874 | 1,347 | 2,757 | |
| Interest expense | 910 | 741 | 1,268 | |
| Other non-operating expense, net | -443 | -12,495 | -33,523 | |
| Total non-operating income (expenses), net | 86,206 | -9,482 | -46,290 | |
| Income (loss) before income taxes | 141,137 | -6,339 | -65,390 | |
| Income tax expense | 23,864 | 833 | -13,479 | |
| Net (loss) income from continuing operations | - | -7,172 | -51,911 | |
| Net income (loss) | 117,273 | -7,172 | -51,911 | |
| Basic net income (loss) per share (in usd per share) | 5.99 | -0.39 | -2.88 | |
| Diluted net income (loss) per share (in usd per share) | 5.68 | -0.39 | -2.88 | |
| Shares used in basic per share calculation (in shares) | 19,578,000 | 18,419,000 | 18,028,000 | |
| Shares used in diluted per share calculation (in shares) | 20,629,000 | 18,419,000 | 18,028,000 | |
LIGAND PHARMACEUTICALS INC (LGND)
LIGAND PHARMACEUTICALS INC (LGND)